Genscript Biotech (G51) Income Statement
Genscript Biotech Income Statement
Last quarter (Q2 2026), Genscript Biotech's total revenue was $403.25M, an increase of 41.41% from the same quarter last year. In Q2, Genscript Biotech's net income was $-129.03M. See Genscript Biotech’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 959.53M | $ 594.49M | $ 560.48M | $ 625.70M | $ 490.10M | |
| $ 553.20M | $ 272.13M | $ 270.63M | $ 304.08M | $ 282.52M | |
| $ 297.96M | $ 262.84M | $ 244.44M | $ 742.06M | $ 661.81M | |
| Depreciation and Amortization | $ 74.04M | $ 73.87M | $ 74.05M | $ 64.25M | $ 47.79M |
| $ 329.29M | $ 83.16M | $ 100.24M | $ -373.73M | $ -467.19M | |
| $ 255.25M | $ 9.28M | $ 26.19M | $ -438.11M | $ -379.29M | |
| $ -725.78M | $ -180.08M | $ 142.69M | $ 6.29M | $ -138.07M | |
| $ -470.53M | $ -170.80M | $ 168.88M | $ -431.69M | $ -517.36M | |
| $ -532.83M | $ 2.96B | $ -95.48M | $ -226.85M | $ -358.71M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.25 | $ -0.03 | $ 0.20 | $ -0.11 | $ -0.18 |
| Diluted EPS | $ -0.25 | $ -0.03 | $ 0.20 | $ -0.11 | $ -0.18 |
| Weighted Average Shares Outstanding | 2.17B | 2.18B | 2.11B | 2.10B | 2.03B |
| Weighted Average Shares Outstanding (Diluted) | 2.19B | 2.18B | 2.11B | 2.10B | 2.03B |
Currency in USD
